172 related articles for article (PubMed ID: 34731019)
1. Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.
Lu SC; Hansen MJ; Hemsath JR; Parrett BJ; Zell BN; Barry MA
Hum Gene Ther; 2022 Mar; 33(5-6):250-261. PubMed ID: 34731019
[TBL] [Abstract][Full Text] [Related]
2. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
3. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
4. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
Hinterberger M; Giessel R; Fiore G; Graebnitz F; Bathke B; Wennier S; Chaplin P; Melero I; Suter M; Lauterbach H; Berraondo P; Hochrein H; Medina-Echeverz J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579736
[No Abstract] [Full Text] [Related]
6. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models.
Liu W; Wang X; Feng X; Yu J; Liu X; Jia X; Zhang H; Wu H; Wang C; Wu J; Yu B; Yu X
Cancer Lett; 2022 Jun; 535():215661. PubMed ID: 35325845
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.
Huang JH; Zhang SN; Choi KJ; Choi IK; Kim JH; Lee MG; Lee M; Kim H; Yun CO
Mol Ther; 2010 Feb; 18(2):264-74. PubMed ID: 19738604
[TBL] [Abstract][Full Text] [Related]
8. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
10. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
Wang Q; Yang M; Zhang Y; Zhong L; Zheng X
Curr Gene Ther; 2019; 19(1):54-65. PubMed ID: 30848201
[TBL] [Abstract][Full Text] [Related]
11. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
Powell KL; Stephens AS; Ralph SJ
Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
[TBL] [Abstract][Full Text] [Related]
12. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
[TBL] [Abstract][Full Text] [Related]
14. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
[TBL] [Abstract][Full Text] [Related]
15. [Immunological killing effect of recombicant adenovirus vector rAD-mTERT-m4-1BBL on mouse hepatoma cell line Hepa1-6 cells co-cultured with T lymphocytes].
Xiao ZS; Ma SY; Gong WD; Yao HH; DU P; Xing YQ; Wu HR
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):894-8. PubMed ID: 20193326
[TBL] [Abstract][Full Text] [Related]
16. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand.
Kim HS; Kim-Schulze S; Kim DW; Kaufman HL
Cancer Res; 2009 Nov; 69(21):8516-25. PubMed ID: 19843856
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effect of 4-1BBL combined with Hsp70-tumor antigen peptides on pulmonary metastasis of melanoma in mice].
Qiu H; Zhang GM; Zhang H; Yuan Y; Li D; Feng ZH
Ai Zheng; 2005 Jul; 24(7):781-6. PubMed ID: 16004800
[TBL] [Abstract][Full Text] [Related]
19. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
Wenthe J; Naseri S; Labani-Motlagh A; Enblad G; Wikström KI; Eriksson E; Loskog A; Lövgren T
Cancer Immunol Immunother; 2021 Oct; 70(10):2851-2865. PubMed ID: 33666760
[TBL] [Abstract][Full Text] [Related]
20. A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells.
Liljenfeldt L; Yu D; Chen L; Essand M; Mangsbo SM
J Immunother; 2014 Apr; 37(3):155-62. PubMed ID: 24598450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]